Author: Steve Kopczak

    • Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Non-carriers.
    • Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH.
    • Clin Breast Cancer. 2022 Dec 21:S1526-8209(22)00290-7. doi: 10.1016/j.clbc.2022.12.012. Epub ahead of print.

    Related:

    •• Identifier: NCT01468246: The Young Women's Breast Cancer Study (HOHO). (ClinicalTrials.gov . Accessed 2022 Dec 21.)

    • LitAlert ~~ GeneLit.com

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2023 Jan 1;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.

    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.

    • European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC.
    • Ryan C.
    • OncLive. 2022 Dec 21.

    • LitAlert ~~ GeneLit.com

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2023 Jan 1;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.

    • European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC.
    • Ryan C.
    • OncLive. 2022 Dec 21.

    • LitAlert ~~ GeneLit.com

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2023 Jan 1;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.

    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.

    • Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Non-carriers.
    • Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH.
    • Clin Breast Cancer. 2022 Dec 21:S1526-8209(22)00290-7. doi: 10.1016/j.clbc.2022.12.012. Epub ahead of print.

    Related:

    •• Identifier: NCT01468246: The Young Women's Breast Cancer Study (HOHO). (ClinicalTrials.gov . Accessed 2022 Dec 21.)

    • European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC.
    • Ryan C.
    • OncLive. 2022 Dec 21.

    • A systematic method for detecting abnormal mRNA splicing and assessing its clinical impact in individuals undergoing genetic testing for hereditary cancer syndromes.
    • Kamps-Hughes N, Carlton VEH, Fresard L, Osazuwa S, Starks E, Vincent JJ, Albritton S, Nussbaum RL, Nykamp K.
    • J Mol Diagn. 2022 Dec 20:S1525-1578(22)00348-8. doi: 10.1016/j.jmoldx.2022.12.002. Epub ahead of print.

    • CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    • Lu X, He Y, Johnston RL, Nanayakarra D, Sankarasubramanian S, Lopez JA, Friedlander M, Kalimutho M, Hooper JD, Raninga PV, Khanna KK.
    • J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.

    • CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    • Lu X, He Y, Johnston RL, Nanayakarra D, Sankarasubramanian S, Lopez JA, Friedlander M, Kalimutho M, Hooper JD, Raninga PV, Khanna KK.
    • J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.

    • LitAlert ~~ GeneLit.com

    • Genetic testing in privately insured women with surgically treated breast cancer.
    • Dinan MA, Pitafi S, Greenup RA, Long JB, Gross CP.
    • Breast Cancer Res Treat. 2022 Dec 21. doi: 10.1007/s10549-022-06829-4. Epub ahead of print.

    • CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    • Lu X, He Y, Johnston RL, Nanayakarra D, Sankarasubramanian S, Lopez JA, Friedlander M, Kalimutho M, Hooper JD, Raninga PV, Khanna KK.
    • J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.